Home Blog Page 81

Regent Hong Kong Celebrates Four Decades of Cantonese Culinary Excellence as Lai Ching Heen Preserves Its Legacy for Future Generations

By
Advertorial Desk
-

SINGAPORE – Media OutReach Newswire – 14 September 2026 – Regent Hong Kong highlights the four-decade culinary legacy of Lai Ching Heen, where Executive Chef Lau Yiu Fai and Head Chef Cheng Man Sang continue to preserve and pass on Cantonese techniques, flavour knowledge and craftsmanship to the next generation of chefs.

Part of Regent Hong Kong and its wider Dining Destination, Lai Ching Heen has built its reputation on refined Cantonese dining, consistency and culinary knowledge developed over time. Its story goes beyond accolades, with much of its character shaped by knowledge shared in the kitchen and carried forward through the longstanding collaboration between Chef Lau and Chef Cheng.

With a legacy spanning four decades, Lai Ching Heen is recognised for refined Cantonese dining, but its story goes beyond accolades. Much of its character comes from knowledge built over time and shared in the kitchen, led today by Executive Chef Lau Yiu Fai and Head Chef Cheng Man Sang. The point is not to hold the past still, but to know what is worth carrying forward.

A Living Expression of Cantonese Heritage

Cantonese cooking often looks simpler than it is. Steaming, double-boiling, roasting and wok cooking leave little room to hide; the result depends on timing, heat and restraint. Seasonality matters, but so does knowing when to step back and let the ingredient speak for itself.

That judgement is difficult to put into a recipe. It is learnt through repetition, observation and small corrections made over years.

At Lai Ching Heen, traditional Cantonese cooking techniques are part of the restaurant’s foundation, not as a fixed rulebook but as practical knowledge that is used and refined. This is how Cantonese culinary heritage stays alive in the kitchen rather than becoming something preserved only in theory.

The People Behind the Craft

Executive Chef Lau Yiu Fai has been closely associated with the hotel since 1980, building deep knowledge of Cantonese cuisine while continually evolving his cooking.

Head Chef Cheng Man Sang has worked alongside Chef Lau for more than 25 years. Their long collaboration gives Lai Ching Heen a shared understanding of taste, technique and standards that has developed over decades.

In a busy kitchen, that shared language matters. Decisions about texture, seasoning or when a dish needs one less flourish are made constantly. Over time, those decisions become instinctive and are passed through the team.

Chef Lau and Chef Cheng therefore preserve more than individual dishes. Together, they help maintain the way the kitchen approaches Cantonese cooking and ensure that its standards continue beyond one generation of chefs.

Cantonese Culinary Knowledge Across Generations

Many Cantonese skills are still learnt through watching, practising and being corrected.

Knife work can be demonstrated and a method can be explained, but heat control, timing and texture only become reliable after a cook has repeated them often enough to recognise the difference for themselves.

This is where mentorship becomes important.

At Lai Ching Heen, the restaurant’s identity does not rest with a single chef. It is reinforced by shared standards across the kitchen, so the reasoning behind a technique can travel with it.

This human exchange is central to how culinary knowledge is maintained and passed from one generation to the next.

Preserving Tradition Without Standing Still

Respecting tradition does not mean reproducing the same dishes in exactly the same way forever.

Cantonese cuisine stays relevant when its fundamentals are understood well enough to support change. Chef Lau’s approach reflects that balance, refining familiar flavours while creating new expressions from established techniques.

At Lai Ching Heen, ingredients, presentation and creative details can evolve, while the essentials remain clear: quality, seasonality, balance and precision.

That balance defines the restaurant’s approach to authentic Cantonese fine dining — contemporary in expression, while remaining recognisably Cantonese at heart.

Recognition Within Hong Kong’s Fine-Dining Landscape

Lai Ching Heen has maintained MICHELIN-star recognition for 17 consecutive years and was awarded Two Stars in the MICHELIN Guide Hong Kong & Macau 2026.

The restaurant also holds Two Diamonds in the Black Pearl Restaurant Guide 2026, alongside other recognition within Hong Kong’s dining landscape.

These accolades reflect the restaurant’s consistency, but its culinary identity remains rooted in the knowledge, standards and techniques maintained within its kitchen.

Under the leadership of Chef Lau and Chef Cheng, Lai Ching Heen continues to combine established Cantonese methods with contemporary refinement while maintaining the principles that have shaped the restaurant over four decades.

Cantonese Craftsmanship Within Regent Hong Kong

That sense of continuity also fits naturally within Regent Hong Kong’s approach to hospitality.

Through the hotel’s Regent Distinction, the experience is built around thoughtful details, a strong sense of place and moments designed to be savoured. Lai Ching Heen brings the same attention to detail to the table through precision and close attention to how each ingredient is handled.

The jade-inspired dining room, conceived as a jewellery box revealing Cantonese culinary treasures, provides a setting that reflects the restaurant’s cultural identity and connection to Cantonese culinary traditions.

Within Regent Hong Kong, Lai Ching Heen represents both continuity and evolution: a restaurant shaped by decades of knowledge while continuing to develop for future generations.

A Cantonese Legacy That Continues to Evolve

At Regent Hong Kong, the story of Lai Ching Heen is ultimately about people and the craft they choose to carry forward.

Chef Lau, Chef Cheng and the team around them demonstrate how a restaurant can respect its history without becoming fixed in it.

The techniques remain precise, the flavours remain recognisably Cantonese, and younger chefs learn not only what to do, but why it matters.

Through that continued transfer of knowledge, Lai Ching Heen remains a living expression of Cantonese culinary heritage within Regent Hong Kong.

Hashtag: #RegentHongKong

The issuer is solely responsible for the content of this announcement.

About Regent Hong Kong

is an iconic luxury hotel situated on Kowloon’s Victoria Harbour waterfront at 18 Salisbury Road.

Following the most extensive transformation in its history, the hotel returned to its Regent heritage with interiors by Hong Kong-born designer Chi Wing Lo. Its 497 guestrooms and suites are complemented by panoramic harbour views and a collection of dining destinations including Lai Ching Heen, The Steak House, Harbourside, The Lobby Lounge, Nobu Hong Kong and Qura Bar.

Regent Hong Kong builds on a hospitality legacy dating to its original Regent era from 1980 to 2001 while introducing a contemporary interpretation of the brand for today’s guests.

For further information, visit.

Award-Winning WRITERS AT WORK Refines Signature Writing Programme for 2027 to Develop Future-Ready Thinkers

By
Advertorial Desk
-

The refined Primary Writing Programme strengthens WRITERS AT WORK’s proprietary STORYBANKING® method to help students think independently, sustain focus and tackle increasingly complex questions with confidence.

SINGAPORE – Media OutReach Newswire – 14 September 2026 – WRITERS AT WORK, a Singapore English writing and enrichment provider recognised on the SME500 Singapore 2025 list, will introduce updates to its Primary Writing Programme, formerly the Pure Composition Writing Programme, across its seven centres in Singapore from 2 January 2027, as part of a wider curriculum refresh designed to help students sustain focused, independent thinking in an increasingly fast-paced learning environment.

Award Winning Writers At Work Refines Signature Writing Programme for 2027 To Develop Future-Ready Thinkers

Built for How Students Think Today

WRITERS AT WORK updates its curriculum annually in response to shifts in Singapore’s English examination and education landscape. The 2027 update also responds to how students today process language, sustain focus, and construct ideas, shaped by their environment, technology, and culture. As attention spans shorten in a faster, more visually driven world, the ability to sit with a difficult question and think it through has become more valuable. The renamed Primary Writing Programme reflects this shift, still anchored in composition instruction but built around how students actually develop writing competency today.

Three Updates to the Primary Writing Programme

Three updates anchor the programme. Under Flexible Writing Practice, students complete guided or independent compositions depending on lesson objectives, with the STORYBANKING® method recalibrated to sharpen critical thinking through adjusted pacing and difficulty. This gradual release of support, from guided modelling to independent application, meets students at different levels of readiness: those who need more guidance receive clearer structure, while more confident writers are pushed to transfer their learning independently and make more sophisticated writing choices.

The update also responds to a reality of how students learn today: with model compositions and ready-made phrases widely accessible, that accessibility is not itself the concern. The risk is students learning techniques without learning to think. Primary Writing Programme lessons are designed to keep that thinking process intact and complete within the lesson, so students build the ability to reason through difficult questions themselves, rather than simply recall a technique.

Selected modules also integrate bite-sized situational writing, oral, and listening comprehension practice alongside composition, giving students regular, low-stakes exposure to other examination components while reinforcing skills they have already built. The STORYBANKING® programme has also been expanded with material tied to current experiences and trends, building on rather than replacing existing content.

A Refresh for the Comprehensive English Programme

The Comprehensive English Programme, covering Primary and Secondary levels, is also being updated, with a focus on strengthening students’ ability to analyse questions and organise ideas. Existing scaffolding within the programme is being broken down further to make the thinking process more visible and explicit to students.

“The updates are not a departure from what has worked. They are a deliberate response to how our students engage with the world today,” said Jemmies Siew, Managing Director and Curriculum Director at WRITERS AT WORK. “Our aim is for students to leave each lesson still knowing how to think through a hard question themselves, not just recall a technique.”

Hashtag: #WritersAtWork #EnglishTuitioninSingapore



The issuer is solely responsible for the content of this announcement.

Writers At Work

is a Singapore English writing and enrichment provider founded in 2012. Its curriculum is built around a structured, results-oriented approach and a proprietary methodology called STORYBANKING®, and has expanded to include writing, comprehension, and oral communication instruction for Primary and Secondary levels across seven centres in Singapore. The company was recognised on the SME500 Singapore 2025 list and has a 14-year track record of students achieving full marks in composition and oral examinations.

Hao Yi Tou’s Tang Plaza Outlet Marks One Year of Business Class Reflexology

By
Advertorial Desk
-

SINGAPORE – Media OutReach Newswire – 14 September 2026 – Hao Yi Tou, a Singapore-based body massage and foot reflexology brand, marked one year of operations at its Tang Plaza outlet on Orchard Road in August. The outlet opened in August 2025 around a ‘business class’ concept that lets professionals in the surrounding Central Business District (CBD) continue working through their reflexology sessions.

Hao Yi Tou's Tang Plaza Outlet Marks One Year of Business Class Reflexology
Hao Yi Tou’s Tang Plaza Outlet Marks One Year of Business Class Reflexology

A Year Built Around the CBD Schedule

Hao Yi Tou’s outlets, including Tang Plaza, were designed around a pattern the company observed among CBD professionals: many treat time away from their desks as a scheduling cost rather than genuine rest, and often delay or skip breaks altogether. Each reflexology seat at Tang Plaza includes a pull-out stand sized for a laptop or mobile device, along with an iPad and charging points, allowing customers to respond to messages or continue working without leaving the massage chair. A year on, Hao Yi Tou said the setup remains among the few in Singapore’s reflexology sector designed specifically around uninterrupted work sessions.

Hao Yi Tou does not require customers to purchase packages or memberships, a departure from common practice in Singapore’s massage industry. ‘Many customers walk in expecting to be sold a package before they even sit down,’ said Darren [Surname], Founder of Hao Yi Tou, reflecting on the outlet’s first year. ‘We built Tang Plaza around the opposite experience. Customers pay for the session they take, nothing more, and our therapists are trained to focus on the massage, not the upsell.’

The Track Record Behind the Concept

Therapists at both Hao Yi Tou outlets have between 10 and 40 years of experience, a contrast to an industry where staff turnover is common. Darren’s approach to service design draws in part from his other role as Managing Director of Peach Garden, a Singapore restaurant group, where he oversaw how hospitality staff manage customer flow and service pacing. He applied similar thinking to how sessions were structured when Tang Plaza opened, an approach the outlet has kept through its first year.

Hao Yi Tou operates a second outlet at Northpoint City in Yishun, which places a stronger focus on acupressure treatments for residents in the surrounding area. As Tang Plaza enters its second year, the company said the outlet will continue on the same basis it opened with: per-session pricing, no packages or memberships, and a setup built for customers who need to stay reachable during a session.
Hashtag: #Business #HaoYiTou #Entrepreneurship #Wellness #Health #Singapore



The issuer is solely responsible for the content of this announcement.

About Hao Yi Tou

Hao Yi Tou (好意头) is a Singapore-based wellness brand established in 2021, offering professional body massage and foot reflexology. Its services include foot reflexology, full body and aromatherapy massage, and optional neck, shoulder, and head treatments. The company operates two outlets in Singapore, at Northpoint City in Yishun and Tang Plaza on Orchard Road, with transparent per-session pricing and no mandatory packages or memberships. More information is available at .

CPO Design Evolution Drives Gen Precision’s Expansion of Custom FAU Inspection for Production Lines

By
Advertorial Desk
-

Gen Precision expands the GTK-OSI1 for production-line inspection of FAUs with up to 80 channels and custom structures, delivering 3σ ≤ 0.1 μm repeatability.

TAOYUAN, Sept. 14, 2026 /PRNewswire/ — Gen Precision is expanding its inspection capabilities for co-packaged optics (CPO) applications as manufacturers seek higher-precision, more flexible inspection of fiber array units (FAUs) and related components. The company now supports FAU configurations with up to 80 channels and custom components with specialized structures, while helping customers deploy these inspection capabilities on production lines to accelerate product qualification and production ramp-up for next-generation optical communications products.

“Passive optical components have traditionally followed standard 1×M or M×N array formats, but AI infrastructure is driving higher-density and increasingly customized designs,” said Jacky Chang, Executive Vice President and Special Assistant to the Chairman at Gen Precision. “Inspection must evolve with these products. By adapting our inspection methods to different designs and validating them with actual customer samples, we help customers advance new optical products with greater confidence.”

Gen Precision has completed inspection and validation projects for multiple customers, including non-standard custom designs, and has shipped its first batch of automated inspection systems.

GTK-OSI1 Expands FAU Inspection to Specialized Structures

Gen Precision has expanded the capability of the GTK-OSI1 Automated Passive Optical Component Inspection Machine beyond standard FAU-related component inspection, adding support for custom components and production-line deployment. By combining AOI-based precision measurement, automation control, AI-powered visual recognition, and software development capabilities, Gen Precision can adapt the system to different component designs.

The GTK-OSI1 delivers measurement repeatability of 3σ ≤ 0.1 μm for Fiber Arrays (FA), V-Grooves, and MT/MMC ferrules. Based on customer sample validation, measurement scripts and fixtures can be customized for deployment in automated production-line workflows. Once specifications are confirmed, Gen Precision can complete system customization and delivery within 6 to 8 months.

Gen Precision expands the GTK-OSI1 for production-line inspection of FAUs with up to 80 channels and custom structures, delivering 3σ ≤ 0.1 μm repeatability.
Gen Precision expands the GTK-OSI1 for production-line inspection of FAUs with up to 80 channels and custom structures, delivering 3σ ≤ 0.1 μm repeatability.

From Component Inspection to CPO Performance Validation

Gen Precision will further extend its optical communications automation capabilities into post-packaging performance testing. In collaboration with Lintes Technology, Gen Precision will develop a CPO test system to validate the performance of packaged products integrating an Optical Engine and FAU. Drawing on its expertise in precision machining, metrology, and automation, the initiative will extend Gen Precision’s capabilities beyond component-level dimensional inspection to include post-packaging performance validation, supporting customers across a broader range of optical product development stages.

About Gen Precision

Established in 1992 and headquartered in Taoyuan, Taiwan, Gen Precision offers fully integrated in-house capabilities in nanoscale precision mold manufacturing, automation system development, and injection molding.

Backed by an ISO 9001–certified quality management system, we deliver key components and integrated automation solutions for semiconductor, optical communications, healthcare, and electronics industries. With long-term global partnerships and customized support, we help customers optimize operations, improve yield, and create lasting value at scale.

Learn more at gentk.com or follow us on LinkedIn.

Meritz Securities Connects to Bruce Markets’ Data Feed for U.S. Equities, Improving Market Data for Korean Traders

By
Advertorial Desk
-

Demand for multi-venue competition grows in South Korea to prevent ‘blind trading’ during U.S. overnight session

CHICAGO and SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ — Bruce Markets, which operates the overnight U.S. equities trading venue Bruce ATS, today announced that Meritz Securities, a leading Korean investment bank and broker-dealer, has connected to Bruce ATS’ market data feed for overnight U.S. equities. The integration provides Meritz Securities with greater visibility into quote and trade activity on Bruce ATS throughout the 8:00 p.m. – 4:00 a.m. ET overnight U.S. session, broadening customers’ view of U.S. equity prices during the Korean business day.

Meritz Securities
Meritz Securities

The milestone comes as South Korean traders fight ‘blind trading’ and reassert their role as one of the most important sources of overnight U.S. equity demand:

  • Korean brokerages resumed daytime access to U.S. stocks in November 2025 following a 15-month suspension, with stronger safeguards and a multi-venue framework.
  • Bruce Markets analysis found that total overnight notional activity nearly doubled between the November reopening and March 2026.
  • Since November 2025, several venue-specific symbol restrictions have reinforced the importance of multi-venue competition. Multiple trading venues help Korean retail traders access pricing data and avoid ‘blind trading’ – a need underscored in September when one venue halted trading in five symbols that collectively averaged 15+ million daily shares in August.

“Healthy markets are built on competition, transparency and choice. Bruce’s share of reported overnight volume nearly doubled in Q2 because market participants increasingly recognize the value of having more than one credible source of liquidity and data,” said Jason Wallach, CEO of Bruce Markets. “Meritz Securities’ connection brings a more complete view of the overnight session in U.S. equities to one of its most important investor bases. That visibility is essential if Korean firms are going to prevent blind trading and deliver the high-quality experience customers deserve.”

Meritz Securities’ connection to Bruce ATS market data reflects accelerating growth in overnight U.S. equities. Across the three leading overnight ATSs, Q2 trading reached 11.14 billion shares and $391.2 billion in notional value – increases of 34% and 59% from Q1, respectively – according to the Bruce Q2 Overnight Market Review.

Bruce ATS accelerated significantly in Q2, with executed volume up 144% to 1.16 billion shares and executed notional up 105% to $49.03 billion. The momentum has continued into September, with Bruce’s share of reported overnight notional climbing from 14.13% to a record 20.77%, and its share of monthly overnight volume rising from 11.66% to 16.4%.

“Meritz Securities is pleased to expand Korean investors’ access to the U.S. overnight equity market through Bruce ATS,” Meritz Securities said in a statement. “This collaboration reflects our commitment to providing clients with broader market access and a stable, reliable trading experience across extended trading hours.”

As Korean demand for U.S. equities continues to expand, a competitive, multi-venue ecosystem ensures market resilience and gives brokers, traders and liquidity providers multiple pathways to see and reach liquidity across a wider range of market conditions.

About Bruce Markets
Bruce Markets operates Bruce ATS™, a U.S. equities alternative trading system enabling overnight trading from 8:00 PM to 4:00 AM ET. Underpinned by exchange-grade technology and market rules, led by industry veterans and backed by leading firms from across the trading ecosystem, Bruce provides a high-performance, resilient venue that bridges the U.S. after-hours and pre-market sessions. By providing a credible source of after-hours liquidity for brokers and investors and leading the evolution of always-available markets, Bruce brings needed competition to the ecosystem and is redefining after-hours trading worldwide. To learn more, visit www.brucemarkets.com.

About Meritz Securities
Meritz Securities Co., Ltd. is a South Korean financial services firm and member of Meritz Financial Group. The company provides securities brokerage, investment banking, sales and trading, and other financial services to retail, institutional and corporate clients. Meritz continues to expand its retail and global investing capabilities through technology-led platforms that bring together trading, information, analysis and investor communities. To learn more, visit home.imeritz.com.

Media Contacts
Forefront Communications for Bruce Markets
bruce@forefrontcomms.com 

Meritz Securities
prd@meritz.co.kr 

FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

By
Advertorial Desk
-
  • Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).
  • Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.
  • FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.
  • Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”).

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

PET imaging with floretyrosine F 18 (FET-PET) is recommended in international clinical practice guidelines for the imaging of gliomas, including NCCN Guidelines®[1], but until now there has not been an FDA-approved product available in the U.S.

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors[2]. In the U.S., approximately 24,000 new glioma cases are diagnosed each year[3], representing a significant unmet addressable need.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”

Kelly Sitkin, President and CEO, American Brain Tumor Association, said, “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said, “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”

About Pixclara (floretyrosine F 18)

Pixclara® is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases[4].

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (177Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Investor Relations

Annie Kasparian
annie.kasparian@telixpharma.com

Charlene Jaw                        
charlene.jaw@telixpharma.com

Media

Eliza Schleifstein

917.763.8106 (Mobile)

eliza@schleifsteinpr.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

[1] Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V3.2026.
[2] Goodenberger et al. Cancer Genet. 2012.
[3] CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022. Neuro-Oncology. 2025.
[4] Investigational New Drug (IND) application successfully cleared, with Study May Proceed notification received from FDA. Telix ASX disclosure August 20, 2026.

 

IonOpticks launches Aurora Series® 5 and new CoreJet™ emitter technology, advancing robust nano-LC for routine proteomics research.

By
Advertorial Desk
-

New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in robustness, lowering cost per sample without compromising the depth and sensitivity researchers depend on.

MELBOURNE, Australia, Sept. 14, 2026 /PRNewswire/ — IonOpticks, the world’s leading manufacturer of high-performance chromatography solutions for LC-MS-based proteomics, today announces the release of Aurora Series 5: the most significant robustness upgrade in the platform’s history. In extended testing on a Thermo Scientific Vanquish Neo UHPLC coupled to an Orbitrap Astral Zoom mass spectrometer, Series 5 sustained over 10,000 unique protein identifications across more than 1,000 injections on an 8-minute, 120-samples-per-day method, with no climb in backpressure beyond 1,400 runs. The result: nanoflow-level depth and sensitivity that laboratories can now run as a routine, high-throughput workflow rather than reserve for landmark experiments.

At the centre of the upgrade are two platform-wide technology developments: CoreJet integrated emitter technology and a redesigned nanoZero union. Together, they deliver more consistent backpressure, improved spray stability and greater reliability over prolonged use without trading away the performance that has established Aurora Series as a benchmark for deep and sensitive proteomics.

“Aurora Series has built its reputation on depth of coverage, sensitivity and reproducibility, but researchers increasingly need exceptional performance they can rely on every day,” says Xavier Perronnet, Chief Executive Officer at IonOpticks. “With Series 5, we have combined that performance with a new level of robustness, giving laboratories the confidence to use these columns routinely across demanding workflows. This is the most significant upgrade we have made to Aurora Series, and an important step towards making exceptional chromatography the everyday standard rather than something reserved for occasional use.”

CoreJet technology introduces a completely redesigned architecture for the integrated pulled emitter, a feature that has always been fundamental to the product. The high-performance CoreJet emitter is fully integrated into the analytical column, ensuring true-zero dead volume post-column and eliminating the concealed unions between column and emitter that create dead-volumes, degrade chromatographic performance and reduce analyte discovery. This new architecture is engineered to deliver substantially greater robustness, improving resistance to early clogging and overpressure events, extending column longevity and supporting prolonged use across increasingly complex sample series.

“True robustness is about more than how long a column lasts. It is about continuing to deliver the depth of coverage, sensitivity and throughput researchers expect, despite the variable and demanding conditions of everyday laboratory use,” says Dr. Jarrod Sandow, Chief Product Officer at IonOpticks. “Across extended testing, Aurora Series 5 maintained its chromatographic performance through more than 1,400 injections. For researchers running everything from individual experiments to large sample cohorts, that means greater confidence that the chromatography will perform consistently, day after day.”

Series 5 also introduces a redesigned nanoZero union, providing a more reliable voltage connection to the liquid passing through the column. Ensuring consistent voltage to the analytical column is essential for stable electrospray ionisation, the process that transfers molecules leaving the column into the mass spectrometer for measurement. By creating a more dependable electrical connection, the redesigned nanoZero union supports further improved spray stability over large sample cohorts while making column setup simpler and easier.

A fundamental priority underpinning Series 5 development was ensuring the new products maintained the strong column-to-column and batch-to-batch reproducibility for which Aurora Series is known. Across all testing, coefficients of variation remain below one per cent for median protein and peptide identifications, supporting consistent performance across a column’s service life and from column to column. Spray stability remains similarly consistent throughout prolonged testing across both instrument platforms. On the Thermo Scientific Vanquish Neo coupled to an Orbitrap Astral Zoom, and the Bruker nanoElute 2 coupled to a timsTOF HT, extended injection series show no spray dropouts, with consistent signal maintained throughout testing. This provides further evidence that Series 5 can sustain stable ionisation and chromatography across prolonged, high-throughput use.

For laboratories processing hundreds or even thousands of samples, the value extends beyond column lifetime alone. Greater stability means fewer unexpected interruptions and column changes, less time spent troubleshooting, more effective use of valuable mass spectrometry capacity, and greater confidence that an extended experiment can continue on a consistent chromatographic platform. This translates to a meaningful reduction in laboratory overheads and helps researchers make better use of both instrument time and research budgets.

When paired with an IonOpticks NanoShield® C18 trap column, Series 5 gains additional protection from sample-derived contamination while significantly reducing sample loading times. By protecting the analytical column from more challenging samples, NanoShield can extend Aurora Series 5 column life even further, creating a workflow that combines speed, lossless protection and high-performance chromatography with an even more compelling value proposition than established market alternatives.

Aurora Series 5 represents a shift in what laboratories can expect from high-performance nanoflow chromatography. The depth and sensitivity remain, but they are now delivered through a platform designed to withstand the demands of everyday proteomics, whether that means a landmark discovery experiment, a large-scale cohort, or the hundreds of routine injections in between.

As Series 5 replaces Aurora Series 4, IonOpticks will retain limited Series 4 stock during the transition period to support continuity for existing customers and ongoing studies. Aurora Series 5 with CoreJet integrated emitter technology is available across the range from 15 September 2026, directly from IonOpticks and through its global distribution network. 

About IonOpticks

IonOpticks is a global leader in high-performance chromatography solutions, empowering the research community to push the boundaries of LC-MS and advanced proteomics. By dramatically enhancing the sensitivity and reliability of mass spectrometry, IonOpticks enables scientists and clinicians to uncover more insights from every sample. These innovations drive discovery across diverse applications, including drug development, phosphoproteomics, shotgun proteomics, and clinical research. Trusted by leading laboratories worldwide, IonOpticks combines cutting-edge technology with a commitment to advancing biological and medical science.

For more information about IonOpticks’ products and research impact, please visit www.ionopticks.com.

LOTTE HOTELS & RESORTS Launches Exclusive Travel Pass Featuring Limited-Edition Korean Heritage Transit Cards

By
Advertorial Desk
-

Package combines a one-night stay with collectible T-money cards designed with traditional mother-of-pearl and longevity motifs, plus vouchers across LOTTE affiliates

SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ — LOTTE HOTELS & RESORTS, South Korea’s largest hotel group, today announced the launch of the LOTTE HOTEL REWARDS Exclusive Travel Pass, a package for international visitors that pairs a one-night stay with two limited-edition LOTTE HOTEL T-money transit cards. The pass is available at ten properties in Seoul, Busan and Jeju, with bookings open through December 29, 2026, for stays through December 31, 2026.

LOTTE HOTEL REWARDS Exclusive Travel Pass, designed with traditional mother-of-pearl and longevity motifs
LOTTE HOTEL REWARDS Exclusive Travel Pass, designed with traditional mother-of-pearl and longevity motifs

A Transit Card Designed as a Keepsake

The T-money card is a prepaid transit card used across South Korea for subways, buses and taxis, as well as at convenience stores and affiliated merchants. The limited-edition version created for this package incorporates two elements of Korean decorative tradition: jagae, the mother-of-pearl inlay long used in Korean lacquerware, and sipjangsaeng, the ten symbols of longevity — including the crane, deer, pine and tortoise — that appear in Korean painting and craft as wishes for long life. The design also features the LOTTE World Tower, the tallest building in South Korea.

Each card is preloaded with KRW 3,000 (approximately USD 2), allowing guests to use it immediately upon arrival.

Benefits Across LOTTE Affiliates

The package includes voucher benefits across major LOTTE affiliates:

  • Dining privileges at hotel bakeries and lounges
  • Membership upgrades and shopping benefits at LOTTE DUTY FREE
  • Admission discounts at LOTTE WORLD
  • Shopping perks at LOTTE MART stores nationwide

Availability

The pass is available at ten LOTTE HOTELS & RESORTS properties: THE GRAND LOTTE SEOUL, LOTTE HOTEL WORLD, LOTTE HOTEL BUSAN, L7 BY LOTTE HOTELS (Myeongdong, Hongdae, Gangnam, Haeundae), and LOTTE CITY HOTELS (Myeongdong, Jeju, Guro).

The package is offered exclusively to international members of LOTTE HOTEL REWARDS. Membership is free, and reservations can be made immediately through the official LOTTE HOTELS & RESORTS website (www.lottehotel.com/global) or mobile app under the “Special Offers” page.

1...808182...6,595Page 81 of 6,595